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Abstract. Compared to basic fibroblast growth factor
(bFGF), a widely distributed, broad spectrum mitogen
and mesoderm inducer, acidic fibroblast growth factor
(aFGF) is reported to have an essentially neural distri-
bution and to be undetectable in the early embryo. In
the present investigation, we used immunoblotting and
immunochemistry to assess the cellular and tissue dis-
tributions of aFGF and bFGF in 11-20-d rat embryos.
Immunoblotting of crude and heparin-bound embryo
extracts revealed faint bands at the expected 17-18-kD
and predominant bands at an apparent molecular mass
of 26 to 28-kD (despite reducing conditions) using
multiple specific antibodies for aFGF and bFGF. Pre-
treatment with 8 M urea yielded 18-20413 aFGF and
bFGF and some 24-26-kD bFGF Immunoreactivity
for both aFGF and bFGF was positive and similar in
B
ASIC fibroblast growth factor (bFGF)' and acidic fi-
broblast growth factor (aFGF, also known as heparin-
binding growth factor 1) are closely related polypep-
tides that have a widespread distribution in tissues and have
been extremely well conserved throughout evolution, a fea-
ture that suggests physiological importance (1-3, 5, 8, 26).
However, the precise biological functions ofbFGF and aFGF
in vivo remain largely unknown. In vitro studies have shown
thatthese two peptides have regulatory effects on many cellu-
lar functions, such as proliferation, differentiation, matrix
formation, and cell movement (3, 5, 26, 36) . Because each
of these functions is ofcritical importance during embryonic
development, these growth factors could play a major role
in embryogenesis. Using biochemical and immunological
methods, bFGF and its messenger RNA have been identified
in amphibian oocytes and embryos and its mesoderm-induc-
ing effect has been demonstrated (35-37, 55, 56). Limited
immunohistochemical studies in chicken and rat embryos
have shown that the presence ofbFGF is associated with de-
velopmental events such as angiogenesis and early muscle
morphogenesis (25, 34, 52) . For aFGF, no embryonic distri-
bution has been reported (9, 25, 30, 34).
1. Abbreviations used in this paper: aFGF, acidic fibroblast growth factor;
bFGF, basic fibroblast growth factor.
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the cytoplasm, nuclei, and extracellular matrix of cells
of neuroectodermal and mesodermal origin, while it
was negative in endoderm-derived cells. The distribu-
tion of immunoreactive aFGF and bFGF also showed
changes during development that were associated with
the process of cellular and tissue differentiation. For
example, intensity and extent of immunoreactivity for
both peptides progressively increased in the middle
layer of the spinal cord with increasing differentiation
of the neural cells. The immunostaining patterns were
very similar for aFGF and bFGF for each organ and
at each stage. In conclusion, high molecular mass forms
of immunoreactive aFGF and bFGF are present in the
rat embryo. Acidic FGF and bFGF are both widely
distributed in tissues of neuroectodermal and mesoder-
mal origin, and their distribution was very similar.
In the present study, we have used Western blot techniques
to investigate the expression of aFGF andbFGF in whole rat
embryos. We have also used immunohistochemical tech-
niques to define the cellular and tissue distribution of aFGF
in embryos at different stages of development (from 11 to
20 d of gestation), and to compare the distribution of aFGF
with that of bFGF.
Materials andMethods
We studied 60 Sprague-Dawley rat embryos ranging from 11 to 20 d of
gestation (crown-to-rump length, 2-23 mm) as described (23, 29).
Extraction ofaFGF and bFGFfrom Rat Embryos
After dissecting the placenta and freezing in liquid nitrogen, embryos were
homogenized for 30 s using a Polytran (Brinkmann, Luzern, Switzerland)
in 8-10 vol of 0.5 M NaCl, 20 mM Tris, 3 mM EDTA, 0.2 mM PMSF,
pH 6.5 at 4-10°C. The homogenizedtissue underwent three freeze-thaw cy-
cles and was thencentrifuged at48,000g for 120 min. The clear supernatant
(crude extract) was used for Western blot analysis and bioassays.
The supernatant (1-2 nil), in 0.5 M NaCl, was also batch absorbed over-
night with 0.4 ml heparin-Sepharose beads, while gently rocking. After be-
ing transferred to a column, the beads were washed with 0.6 M NaCl in 10
mM Tris, and were eluted with a step gradient of 1.1, 1.5, and 3.0 M NaCl
in 10 mM Tris. Aliquots were obtained for Western blot analysis and bio-
assays.Antibodies
For identification ofaFGF, two polyclonal antibodies and a monoclonal an-
tibody were used. The twopolyclonal antibodies (#63 and #119) were raised
in rabbit against human/bovine aFGF (residues 65-97, SIG . . . NEE). This
33-amino acid region ofaFGF is only 33 % homologous to fist (58)/K-FGF
(11), FGF-5 (62), and FGF-6 (40). We found cross-reactivity of these two
antibodies with bFGF is 1% in Western blots. The monoclonal antibody
against bovine aFGF (Upstate Biotechnology Inc., Lake Placid, NY) recog-
nizes the tyrosine 111 to lysine 126 region of aFGF, a region with only
12-25% homology with int-2 (12), fist/KFGF (11, 58), and FGF6 (40), and
has very littlecross-reactivity with bFGF (<1% in Western blots, in our lab-
oratory). The stock concentrations for these antibodies were the following:
28 mg/ml for antibody #63; 34 mg/ml for #119; and 1 mg/ml for the mono-
clonal antibody.
For identification of bFGF, three rabbit polyclonal antibodies and five
monoclonal antibodies were used. One (#773) was raised against the first
24 amino acids of bovine bFGF, a region with 100% homology to human
bFGF and 96% homology to rat bFGF, but no homology to the predicted
amino acid sequences ofint-2, fist/K-FGF, FGF-5, FGF-6, or KGF (17) . A
second (#967) was raised against human recombinant bFGF (whole mole-
cule) ; and a third was raised against bFGF COOH-terminal residues AIL
. . . SAK. The antibodies #773 and #967 are IgG purified and were kindly
provided by Dr. Andrew Baird (The Whittier Institute, La Jolla, CA). The
cross-reactivity to aFGF ofantibody #773 is 2% in Western blots, 0.1% in
RIA, and thoseofantibody #967 and the COOH-terminal antibody are<1%
in Western blots. The five monoclonal antibodies were prepared from
BALB/c mice using the hybridoma technique; two of them (mAb #12 and
#78) recognize their epitope located at the first nine residues of the human
recombinant bFGF, a region with no homology to other FGF family mem-
bers; the two remaining monoclonal antibodies (mAb #52 and #98) recog-
nize the site between the amino acid residues 14 and 40. These four mono-
clonal antibodies were the kind gift of the Pharmaceutical Group, Makeda
Chemical Industries, Ltd., Osaka, Japan(54). Thelast monoclonal antibody
wasantibovine basicFGFtype IJantibody from UpstateBiotechnologyInc.,
Lake Placid, NY (cat. No. 05-118). The immunogen for this antibody is
purifiedbovinebrain bFGF. This antibody is highly specific for bFGF from
bovine human, rat, and mouse source and does not cross-react with aFGF.
Each of these monoclonal antibodies showed high specificity, without de-
tectablebinding to aFGF in Westernblots, in our laboratory. Thestock con-
centrations for these antibodies were the following: 2 mg/ml for antibodies
#773 and #967; 18.6 mg/ml for.mAb #12; 2.4 mg/ml for mAb #78; 4.9 mg/
ml for mAb #52; 5.8 mg/ml for mAb #98; and 2 mg/ml for mAb antibovine
bFGF type II.
Western BlotAnalysisforaFGFandbFGF
Crude extracts and column fractions were subjected to SDS-PAGE in 4-20
or 10-20% gradient gels and then transferred to nitrocellulose membrane
(0.05 Am; Schleicher & Schuell, Inc., Keene, NH) by electrophoretic trans-
fer (Polyblot Transfer System, Model SBD-1000; American Bionetics,
Emeryville, CA). To investigate the multiple forms of FGFs, we used
Laemmli buffer with and without 8 M urea (to break up potential ag-
gregates) in a stacking gel buffer of0.0625 M Tris, SDS stock 1%, and di-
thiothreitol 15 mM. The samples were kept at room temperature 1 h, then
4°C overnight, and boiled before loading onto SDS-PAGE. We also used
the adult rat tissue extract as a control. After transfer and blocking of the
nonspecific protein-binding sites with 3% dry milk in TBS, the nitrocellu-
lose membrane was incubated with different antibodies at suitable dilutions
(1:500 for the monoclonal antibody for aFGF, 1:1,000 for the other antibod-
ies) in wash buffer (10 mM Tris-HCI, pH 8.0, 0.15 M NaCl, 0.05% Tween-
20) overnight at 4°C. Antigen-antibody complexes were visualized by in-
cubating the membrane with suitable secondary antibodies and developing
it by ProtoBlot Western Blot AP System (Promega, Madison, WI).
Western blot analyses with a preabsorbed monoclonal antibody and a
polyclonal antibody for aFGF and bFGF (COOH-terminal) were used to
verify the immunospecificity of the staining.
Mitogenicity AssayofEmbryo Extracts
BALB/c/3T3 mouse fibroblasts were subcultured and used for determina-
tion ofgrowth factor activity, as previously described in detail by Hauschka
et al. (28). In brief, Costar 96-well plates were seeded with 1 x 105
cells/well in 200 pl of DMEM and grown for 10 d in 5% CO2, 95% air
incubator at 37°C. Different fractions of embryo extracts were eluted
through heparin-Sepharose columns at 1.1, 1.5, and 3.0 M NaCl, and were
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added to the wells 10 d after cell seeding. Without changing the original
plating medium, 2 /i1 oftest substances and 1 pCi of [3H]thymídine in 1"0
kl of PBS were added to each well. After 48 h of incubation, cells were
harvested and radioactivity was measured using a liquid scintillation ana-
lyzer (1500 TRI-CARB; Packard InstrumentCo., Downers Grove, IL). The
background was 1,600-2,200 cpm/well; maximal serum stimulation was
10-15-fold above background.
Immunohistochemistry
The distributions of aFGF and bFGF were investigated by immuno-
histochemical staining in both sagittal sections and cross-sections of whole
rat embryos at 11-20 d of gestation. In each embryo, one sagittal section
and three to four cross-sections at the level of the brain, heart, and kidneys
were obtained. Embryos were fixed in 4% paraformaldehyde in 0.1 M phos-
phate buffer, pH 7.4, overnight at 4°C. After dehydration through a graded
series ofethanol solutions, several embryos were embedded in one paraffin
block to reduce the interassay variability. Sections from each block (6 um
thick) were stained with H & E, Masson and Yajima (periodic acid-
methenamine silver staining) methods, for routine morphological evalua-
tion. Sections were immunostained using the following steps: (a) blocking
of endogenous peroxidase with 3% hydrogen peroxide in methanol (30
min); (b) treatment with 2 mg/ml hyaluronidase Type IV-S (No. H-3884;
Sigma Chemical Co., St. Louis, MO) in 0.1 M acetate buffer, pH 5.1 (15
min) ; (c) blocking of nonspecific protein binding with 5% goat serum in
50 mM Tris buffer at pH 7.4 (1 h); (d) incubation with primary antibodies,
at suitable dilution at 4°C overnight (for aFGF, 1:1,000 for the polyclonal
antibody #63, 1:500 for the polyclonal antibody #119, and 1:400 for the
monoclonal antibody; for bFGF, dilutions were 1:500 for each antibody
used; (e) incubation withperoxidase-labeled affinity-purified goat anti-rab-
bit IgG for the polyclonal antibodies (Vector Laboratories, Inc., Burlin-
game, CA), and incubation with peroxidase labeled affinity-purified horse
anti-mouse IgG for the monoclonal antibody (Vector Laboratories, Inc.)
(1 h); (f) treatment with 0.25 mg/ml diaminobenzidine (Sigma Chemical
Co.) in 0.05 M Tris-HCI buffered saline containing 0.01% hydrogen perox-
ide (10 min); (g) counterstaining with 1% methyl green solution (2 min).
The buffer solution used for rinsing aftereach step consistedof0.01 M Tris-
HCl buffered saline and 0.25% Brij-35 (Sigma Chemical Co.), at pH 7.4.
All steps, except when otherwise specified, were performed at room tem-
perature.
Immunohistochemical ControlsforaFGFand bFGF
No immunostaining was seen in sections after the following immuno-
histochemical control procedures: (a) omissionofthe primary antibodyand
incubation with normal rabbit serum at the same (or more concentrated)
dilutions used for the primary antibody; (b) omission of the primary anti-
body and incubation with 2% normal goat serum; and (c) omission of the
primary antibody and incubation with nonimmune mouse IgG at the same
(or more concentrated) dilutions used for the primary antibody.
In addition, specificity of immunostaining was confirmed for each anti-
bodyby incubation withprimaryantibodypreabsorbedby its corresponding
growth factor as described below. Two different procedures were used for
absorption ofeach antibody for aFGF and bFGF. (a) After blockingof non-
specific protein binding with 5% goat serum in 50 mM Tris buffer at pH
7.4 (1 h), sections were incubated with preabsorbed antibody at 4°C over-
night. Preabsorbed antibody was obtained as follows: antibody at suitable
dilutions (total volume0.3 ml) was incubatedwith heparin-Sepharose beads
saturated with 100-200 hg ofaFGF orbFGF, at4°C overnight. Supernatant
was used as preabsorbed antibody. (b) After blocking of nonspecificprotein
binding, as in a, specific blocking of FGFs binding sites was obtained as
follows. Sections were incubated with 50-100 #g/ml ofhumanrecombinant
aFGF orbFGF, as appropriate, in 0.2 ml of2% goat serum, at roomtemper-
ature for 1 h and subsequently at 4°C for2 h. Then, sections wereincubated
with primary antibody. For each antibody, and with each procedure, no im-
munostaining was seen in sections. Heparin-Sepharose beads alone (with-
out aFGF or bFGF) did not deplete the antibodies of tissue reactivity.
Results
Identification ofaFGFandbFGFin RatEmbryos
Western blot analysis for aFGF and bFGF was performed in
embryo crude extracts and heparin-bound material obtained
at different stages of development (days 16, 17, and 18). A
1262monoclonal and two polyclonal antibodies for aFGF, and
three polyclonal and five monoclonal antibodies for bFGF,
were used as Western blotting reagents . For aFGF, at each
stage and with each antibody, a band with a molecular mass
of rv 26 kD was detected (Fig . 1), as well as a fainter band
at 18-20 kD. A faint band of 52 kD, perhaps a doublet of 26-
kD aFGF, can also be detected . These bands were com-
pletely suppressedby addinghuman recombinant aFGF, thus
suggesting specificity of antibody binding. After being boiled
in Laemmli buffer with 8 M urea (to more effectively de-
nature and break up aggregates), the 26-kD band became
fainter and 18- and 20-kD immunoreactive bands became
more intense. By contrast, only 18-kD immunoreactive aFGF
was detected in adult rat brain extract (Fig . 1) . For bFGF,
at each stage and with each antibody used, a doublet or a
triplet with a molecular mass from 24 to 28 kD was iden-
tified (Fig . 2), as well as the expected (but fainter) band at
17-18 kD . Bands were significantly suppressed by adding hu-
man recombinant bFGF . As with aFGF, after boiling in 8M
urea with Laemmli buffer, the 28-kD immunoreactive bFGF
band became fainter, and 24-, 22-, and 18-kD bands became
more intense . Although the 18-kD immunoreactive bFGF is
the predominant form in adult rat brain extracts, 24- and
26-kD immunoreactive bFGF also were detected (Fig . 2) .
Mitogenic Activity ofEmbryo Extracts
The mitogenic activity ofembryo extracts is shown in Fig . 3.
Mitogenic activity for 3T3 fibroblasts was present in fractions
that eluted from heparin-Sepharose columns 1 .1 and 1.5 M
NaCl, which is consistent with the heparin affinity ofaFGF
and bFGF, respectively. Crude extracts also showed mito-
genic activity for 3T3 cells (Fig . 3) . Western blots demon-
strated that the 1.1-M fractions contained both aFGF and
bFGF.
Immunohistochemical Localization ofaFGF
The two polyclonal antibodies and the monoclonal antibody
toaFGF used in this study showed a similar pattern of stain-
ing in the rat embryos, with specific tissue distribution of
immunohistochemically detectableaFGF (Figs . 4-7) . Immu-
noreactive aFGF was identified in tissues of neuroectoder-
mal and mesodermal origin . In addition, the distribution of
aFGF showed progressive changes during development both
in the neuroectodermal and mesodermal tissues, and such
changes appeared to be associated with tissue differentiation .
At the cellular level, staining was localized in the cytoplasm,
as well as the extracellular matrix . Faint staining was also
noted in some nuclei . The pattern of immunostaining in in-
dividual organs (described below) was virtually identical for
aFGF and bFGA
Central Nervous System . In the spinal cord, the pattern
ofimmunoreactivity foraFGF was highly specific and showed
progressive and consistent changes from earlier to later
stages of embryonic development . The neuroepithelial cells
that are adjacent to the spinal canal and actively proliferating
showed no immunoreactivity throughout development (Fig .
5, c and d, and 6, c and d) . The mantle zone (middle layer)
showed increasingly more intense staining, from earlier
Figure 1. Western blot analysis of rat embryo extracts for aFGF. (a) Incubated with anti-aFGF monoclonal antibody (mAb) . Lane M,
molecular mass standards ; lane 1, human recombinant aFGF (hraFGF) 100 ng ; lane 2, human recombinant bFGF (100 ng) ; lanes 3-5,
crude extracts of 16-, 17- and 18-d embryo ; 26-kD bands predominate with faint immunoreactivity at 12-16M . (b) Incubated with the
same antibody preabsorbed withaFGF ; lane 1, hraFGF (100 ng) ; lane 2, crude extract of 16-d embryo, no detectable bands . (c) Incubated
with anti-aFGF mAb ; lane 1, bovine aFGF (50 ng) ; 18- and 16-kD bands are shown ; lane 2, hrbFGF (50 ng) ; lane 3, crude extract of
16-d embryo treated with Laemmli buffer plus 8 M urea to dissociate aggregates ; lane 4, same as in lane 3, treated with Laemmli buffer ;
lane 5, 1 .1 M NaCl column eluate from 17-d embryo treated with Laemmli buffer; lane 6, 1 .1 M NaCl column eluate from 16-d embryo
treated with Laemmli buffer; lane 7, same fraction as in lane 6, treated with Laemmli buffer with 8M urea ; lane 8, 1 .1 M NaCl column
eluate from adult rat brain . In all embryo extracts, 26-28-kD bands predominate with faint 18-20 and 55 kD (dimer) immuno-reactivity .
After being treated in buffer with 8M urea, 18- and 20-kD bands predominate and 26-28-kD bands are faint . Only 18-kD band is detected
in adult rat brain extract. (d) Incubated with anti-aFGF polyclonal Ab #119. Lane 1, bovine aFGF (25 ng), 18- and 16-kD bands are shown ;
lane 2, 1 .1M NaCl column fraction from 16-d embryo treated with Laemmli buffer, intense 28-kD band and fainter 18-20-kD bands are
shown ; lane 3, same fraction as in lane 2, treated with Laemmli buffer with 8M urea, 28-kD band becomes fainter and 18-kD band becomes
more intense.
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M, Molecularmass standards; lanes 1-S were same as in Fig . 1A. (Lane 2 illustrates the expected 18-kD band and smaller amounts of
the nonreducible 35-kD dimmes in this preparation of rbFGF) . (B) Incubated with anti-bFGF mAb 1198. (C) Incubated with anti-bFGF
polyclonal antibody C135. The lanes were thesame as inA, 26-28-kD bands predominate, and 17-18-kD bFGF bands in the crude embryo
extracts (lanes 3-5) and proteolytic fragmentsoftherbFGF also areshown . (D)Incubated with preabsorbed antibody C135 . Lane 1, human
recombinant bFGF (hrbFGF) (100 ng) ; lane 2, crude extract of 16-d embryo. Immunoreactive bands were significantly suppressed . (E)
Incubation with mAbtype II. Lane 1, bovine aFGF (50ng) ; lane 2, hrbFGF (50 ng), I8-kD and faint 36-kD bands (dimer) are shown;
lane 3, 1.5M NaCl eluate of 16-d embryo, 28-, 26-, 24-, and 18-kD bands are shown; lane 4, 1.5M NaCl eluate of 16-d embryo treated
with Laemmli buffer with 8M urea, 28-kDband becomes fainter ; 26-, 24,- and 18-kDbands become more intense . Lane 5, 1.5MNaCI
eluate of adult rat brain, 26-, 24-, and 18-kD bands are shown . (F)Incubatedwith anti-bFGF polyclonal antibody C135 ; lane 1, bovine
aFGF (50 ng); lane 2, hrbFGF (30 ng); lanes 3-5 are same as in C . In 1.5 M NaCl eluate of 16-d embryo, 28-kD band and faint 14-
and 18-kD bands are shown. With 8M urea, 28-kD band becomes fainter, and 26- and BAD bands become more intense . In adult rat
brain, 18-kDband ispredominant ; 24-and28-kDbands arevery faint . (G)Immunoblots usinganti-bFGF967ofheparin-Sepharose eluates
of adult rat heart (lane 3), 16-d rat embryo with (lane 5) or without (lane 4) 8M urea in the Laemmli buffer, 17-d embryo with 8 M
urea (lane 6) and 2-wk-old rat brain (lane 7) . 28-kD band is seen only in brain and whole embryo and is disaggregated to 18-kD by
8 M urea . Lane 1, 50 ng aFGF Lane 2, 50 ng bFGF M, relative molecular mass standards .
(days 11-14) to later stages of development (days 15-20)
(Figs . 5, c and d, and 6, c and d) . The white zone showed
intense staining at all stages examined . At the cellular level,
staining for aFGF was positive in the migrating neuroblasts
and differentiated neurons and glia, and it was negative in
some cells located in the anterior horns .
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In the brain, the general pattern of immunoreactivity for
aFGF was similar to that described in the spinal cord (Figs .
5, a and b, and 6, a and b) . The gray matter showed a
progressive increase in thearea positively stained and in the
intensity ofstaining from earlier to later stages ofembryonic
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Figure 3 . Mitogenicity assay for 3T3 cells of crude extracts and
heparin-Sepharose affinity chromatographic fractions of rat em-
bryos aged 16 d . Both crude extracts, 1 .1- and 1.5-M fractions, ex-
hibit mitogenicity in 3T3 cells.
mogeneous staining throughout all stages examined . In the
meninges, inununostaining was also intense and homoge-
neous throughout all the developmental stages examined .
Eye. Immunolocalization ofaFGF in the eye was examined
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during the later stages of development (days 16-20, Fig . 6
a) . The vitreous body and optic nerve stained intensely at
all stages examined . At day 16, the retina showed positive
staining only in the cell layers that were contiguous to the
vitreous body, from days 17-20, the cell layers of the retina
showing positive staining which increased in parallel with
the increasing number of layers. At earlier stages (day 16),
the cornea showed positive staining of epithelial, stromal,
and endothelial layers, but by day 19 it showed positive stain-
ing only in Bowman's and Descemet's membranes .
Heart . The developing heart stained positively for aFGF
at each of the stages studied (Figs . 4 a, S, a and e, and 6 e) .
However, at earlier stages (days 11-13), the intensity ofstain-
ing was less in the endothelial cells of the endocardium than
in the cardiac myocytes (Fig . 5 a) . Staining was also positive
in the mesenchymal cushions from which the heart valves
and the roots of the pulmonary artery and the aorta develop
(Fig . 4 a) . The endothelial cells ofthe capillaries showed non-
uniform staining for aFGF throughout development (Figs.
5eand6e) .
Respiratory System . In the lungs, the pattern ofimmuno-
staining for aFGF remained constant throughout all stages
examined . Connective tissue within the lungs showed posi-
tive staining (Figs.4a, 5f, and 7, a and c) . Immunoreactivity
was more intenseand uniform in the cytoplasm offibroblasts
and in theextracellular matrix . Theepithelium ofthe airways
(which originates from the endoderm) remained negative at
all stages examined, and the smooth muscle layers of the air-
ways showed only faint staining (Figs 5 f, and 7, a and c) .
During development of the lungs, there is a progressive in-
crease in the amount ofbronchial epithelial tissue relative to
the amount of connective tissue; thus, the lungs showed sub-
stantially less immunoreactivity at later stages (days 19-20)
than at earlier stages (days 13-14, see Figs. 5f and 7 c) .
In the trachea, the pattern of inununostaining for aFGF
was similar to that of the lungs (Fig. 7 a) . The fibroblasts
and extracellular matrix of the connective tissue showed the
most intense immunoreactivity, while chondroblasts and
Figure 4. Sagittal sections of 15-d rat embryo . (a) Immunoreactive aFGF (antibody í4l119) is present in the heart and surrounding mesen-
chymal tissues, and it is absent in the liver (Li) and the epithelia of the digestive system (arrow) and respiratory system (arrow*ead) .
(b) Inununostaining for aFGF is negative after incubation with preabsorbed Ab ít119. Bars, 100 Am.Figure5 . Immunolocalization of aFGF in 11-14-d rat embryos. (a) Sagittal section of 11-d embryo stained withAb 1163 ; positive immuno-
staining is seen in the heart, brain, mesenchymal tissues, andsomites . (ó) Sagittal section of 11-d embryo stained withmAbshows positive
immunostaining of brain and mesenchyme (M) ; staining is more positive in the outer (more differentiated) layers of the brain . (c) Cross
section ofthe spinal cord of 14-d embryo stained with Ab 1163 ; staining is positive in the mantle zone or middle layer (M) andthe white
zone (W), and it is negative in the less differentiated ependyma (E). (d) Same section as in c, but at higher magnification ; positive staining
is seen in the cytoplasm of the migrating neuroblasts and the extracellular matrix . (e) Detail of part of a, showing sagittal section of the
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and nonuniform staining. Smooth muscle in the wall of the
trachea and in the media of the vessels showed only faint
staining. The tracheal epithelium showed no immunoreac-
tivity at any of the stages examined.
Kidneys. The pattern of staining for aFGF in the kidneys
remained constant throughout all stages examined (Figs. 5
fand 6 c). Connective tissue showed intense staining, while
the epithelium of the tubules showed no immunoreactivity.
Thus, at later stages, when the cortex and the medulla could
be clearly identified, the cortex (containing a high percent-
age ofepithelial cells) showed substantially less staining than
the medulla (rich in connectivetissue) (Fig. 6 c) . The kidney
capsule, which is composed of connective tissue, showed
positive immunoreactivity at all stages examined.
Digestive System. In the esophagus, the connective tissue
showed intense immunoreactivity for aFGF, the epithelium
showed no staining, and the smooth muscle cells showed non-
uniform and weak staining. The same pattern of immuno-
staining was present in the stomach and intestines (Fig. 6f).
In the liver, the hepatocytes showed no staining throughout
all stages examined (Figs. 4 a, 5f, and 6f) . Only the endo-
thelial cells of the hepatic sinusoids, veins and arteries, and
foci of hematopoiesis showed positive staining (Fig. 5 f).
Skeleton. At early stages ofembryonic development (days
11-12), the somites constituting the axial skeleton showed
positive staining for aFGF, with the peptide beingpresent in
the cytoplasm ofmost ofthe cells (Fig. 5 a). At later stages,
when somites were clearly differentiated into sclerotome,
myotome, and dermatome, the chondroblasts and osteoblasts
showed positive staining, while the perichondrium and the
periosteum showed no immunoreactivity. The three endo-
chondral primary ossification centers ofthe vertebrae, which
became apparent at 15-16 d, showed intense staining, and
the immunoreactivity of the ossification centers was clearly
higher than that ofthe surrounding chondroblasts (Fig. 6 c) .
Throughout all stages of long bone development (13-20 d),
the limbs showed predominantly positive and diffuse staining
for aFGR In particular, the areas of intramembranous ossi-
fication and the contiguous osteoblasts showed intense stain-
ing. Conversely, the perichondrium and periosteum showed
no immunoreactivity (Fig. 7 b).
SkeletalMuscle. At earlier stages (11-14 d), skeletal mus-
cle cell precursors that were adjacent to the developingver-
tebrae showed positive and homogenous staining for aFGF
(Fig. 5, a andf) . At later stages (16-18 d), when the skeletal
myoblasts could first be identified, the cytoplasm ofthe my-
oblasts also showed positive inununoreactivity (Figs. 6dand
7 b). Atlater stages ofdevelopment (days 18-20) the skeletal
muscle showed less intense staining.
Thymus. Neither the cortex nor the medulla ofthe thymus
showed any immunoreactivity for aFGF, throughout all
stages examined. The connectivetissue that forms the organ
capsule and divides it intolobes, showed positive and intense
staining throughout all stages examined (Fig. 7 d) .
Comparison ofImmunohistochemicalLocalization
ofaFGFandbFGF
The cellular and tissue distribution of bFGF was substan-
tially similar to that of aFGR Multiple antisera directed
against several epitopes of bFGF gave identical results. The
general distribution of immunoreactive bFGF is shown in
serial sections (Fig. 7, e and f) .
NaturalFormsofaFGFandbFGF
Acidic FGF is a single chain peptide composed of 140-154
amino acids and its molecular mass has been reportedto vary
between 15 and 18 kD, depending on the different cells, or-
gans, and species of origin (5, 59) and extraction methods.
Acidic FGF has a high degree of structural homology with
bFGF, a more extensively investigated growth factor that has
a range of molecular masses (18, 19, 26, 32, 45, 57) . Re-
cently, a heparin-binding immunoreactive bFGF-like protein
of high molecular mass (25 kD) has been identified in ex-
tracts of adult rat liver (45). In addition, a 25-kD bFGF has
been purified from guinea pig brain tissue and appears to be
an NHZ-terminally extended and posttranslationally modi-
fied form of bFGF (57) . In the present investigation, we
identified high molecular mass forms for both aFGF and
bFGA Western blot analysis, performed onrat embryo crude
extracts and heparin-bound material, using several highly
specific polyclonal and monoclonal antibodies, identified
26-28-kD molecular mass forms of aFGF and 24-28-kD
bFGA Specificity is suggested by the fact thatthe same bands
are detected by different antibodies corresponding to differ-
ent residues of FGFs and are suppressed by the correspond-
ing FGFs. The absence of high molecular forms of immu-
noreactive aFGF in adult brain extract indicates that the high
molecular mass forms of immunoreactive aFGF (and bFGF)
are developmentally regulated. Moreover these peptides were
mitogenic for 3T3 cells. These appeared to be the main im-
munoreactive forms of the two peptides in the rat embryo.
Genomic clones and cDNA of bFGF predict a 17.8-kD
(155 amino acids) gene product, based on the presence of a
single putative translation-initiating ATG colon. In a previ-
ous study, multiple molecular forms of bFGF (17.8, 22.5,
23.1 and 24.2 kD) were identified in the human hepatoma
cell line SK-HEP1 (18). In that study, an SKHEP1 bFGF
cDNA was used to show that in vitro transcription-transla-
tion, as well as in vivo COS-1 cell expression experiments,
result in the synthesis of multiple bFGF protein species.
Selective mutagenesis of this cDNA demonstrated that the
translation of the 17.8-kD protein is initiated at the previ-
ously predicted AUG colon, while the translation of the
22.5-, 23.1-, and 24.2-kD proteins is initiated at CUG
codons. Therefore, it would appear that the higher molecular
mass forms of bFGF are the colinear NHZ-terminal exten-
heart of an 11-d embryo stained with Ab #63; staining is positive in the cytoplasm of the myocytes and in the extracellular matrix, and
it is nonuniform in the endothelial cells (arrows), some cells showing positive and other cells negative staining. (f) Sagittal section of
14-d embryo stained with Ab #119; staining is positive in the mesenchyme of the lungs (Lg) and kidneys (K), and it is negative in the
liver (Lt) and in the epithelium of the lungs and kidneys. Bars, 50 gym.
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DiscussionFigure6 . Immunolocalization ofaFGF in rat embryos at later stages ofdevelopment (16-20 d) . (a) Cross section ofbrainand eye of 19-d
embryo stained withAb #63 . Immunostaining is positive in the braincortex (arrow), in the layers ofthe retina (R) contiguous to the vitreous
body, in the capillary network and anterior lens epithelium . (6) Sagittal section of brain of 17-d embryo stained with mAb; staining is
more positive in the outer (more differentiated) layers than in the inner (less differentiated) layers of the brain, and it is also positive in
the skin (S) . (c) Cross section of 19-d embryo at kidney level stained with Ab #119 ; staining is positive in the spinal cord, ossification
centers of the vertebrae (arrows), and mesenchymal tissue of the kidneys (K); it is faint in the media of the aorta (A) and negative in
the cortex of the kidneys. (d) Cross section of the spinal cord of 16 d embryo stained with AB #63 : staining is positive in the mantle
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1268sions of the 17.8-kD bFGR In contrast, the aFGF gene has
an inframe stop codonjust 5' to the start codon. Thus, nei-
ther gene predicts products of >25 kD. Adding 8 M urea at
100°C before SDS-PAGE under denaturing conditions dis-
sociated the embryonic 28-kD bFGF to the expected 24- and
18-kD forms. The identities of the 28-kD immunoreactive
aFGF and bFGF found when SDS-PAGE is performed with-
out urea are not known. Addition of 8 M urea may dissociate
some small binding protein, yielding the expected forms of
aFGF and bFGF. The roles of high molecular mass aFGF
and bFGF are not known. Recent data suggest a nuclear role
for these forms (46) .
ImmunohistochemicalLocalization ofaFGF
Previous observations support the hypothesis that aFGF and
bFGF stimulate proliferation and differentiation of em-
bryonic tissues (36, 55, 61) . However, the embryonic distri-
bution of aFGF has not been reported. In the present study,
immunoreactive aFGF was widely distributed and regulated
in tissues of neuroectodermal and mesodermal origin.
Central Nervous System. Both FGFs have previously
been extracted from brain tissue (5, 15, 48) but their biologi-
cal functions in the development of the central nervous sys-
tem remain unknown. There is in vitro evidence that these
growth factors stimulate proliferation and differentiation of
nervous cells, and favorably influence their survival. Basic
FGF has been shown to enhance neurite growth and survival
in hippocampal, mesencephalic, dopaminergic, and GABA-
ergic neurons, and in PC 12 cells (2, 13, 16, 38, 42, 60), and
it also has been reported to have mitogenic effects on glial
and Schwann cells, chromaffin cells, and embryonic neuro-
blasts which later express cholinergic differentiation (10,
22). Acidic FGF is mitogenic for Schwann cells (10), chemo-
tactic for astroglia and enhances process formation in retinal
sensory neurons (53).
While the cellular localization ofbFGF in the central ner-
vous system of the adult rat has been reported previously
(14), that of aFGF has never been described and the em-
bryonic neural distributions of both FGFs are unknown. In
the present study, immunoreactive aFGF was widely dis-
tributed in the cytoplasm of the migrating neuroblasts, neu-
rons, astroglia, and glia and was not identified in the
undifferentiated and proliferating neuroepithelial cells that
are adjacent to the lumen of the central tube of the spinal
cord and to the lumen of the ventricles (23). We also identi-
fied changes in the distribution ofimmunoreactive aFGF that
paralleled the changes in cell differentiation that accompany
organogenesis. For example, whilethe differentiating cellsof
the gray matter and whitematter showed progressively more
intense and homogenous staining during development, the
undifferentiated cells of the ependyma showed no immu-
noreactivity throughout all the stages examined. The pro-
gressive increase in aFGF in the central nervous system is
more consistent with a role in synapse formation, transmis-
sion or trophísm than in proliferation per se. The accumula-
tion of apparently extracellular aFGF coincides with, and
may contribute to, capillary invasion in the central nervous
system. These findings suggest that aFGF plays an active role
in the morphogenesis ofthe central nervous system in the rat
embryo.
In the anterior horns of the spinal cord, the majority of
motor neurons die after failing to establish synapses with
skeletal myocytes (33). Motor neurons with processes showed
intense staining for aFGF, while cells with few or no pro-
cesses showed no staining. This finding suggests that the loss
of aFGF might also have a role as a signal for programmed
cell death.
Eye. Acidic FGF and bFGF have previously been isolated
from adult and embryo retina (4, 27, 41, 43). In this report,
we describe the coexpression ofaFGF and bFGF in the optic
nerve and in the innermost developing layers of the retina,
probably corresponding to the future nerve fiber layer and
ganglion cell layers, and perhaps the inner plexiform and nu-
clear layers. Until several weeks after birth, and subsequent
opening ofthe eyelids, these layers are not well differentiated
and the retina is poorly vascularized (27). These facts may
explain the differences between our observations and those
reported in adult retina, where aFGF mRNAandpeptide are
widely distributed, whereas bFGF mRNA is reported only
in the photoreceptor layer (7, 42), although the peptide is
also found in the cultured retinal pigment epithelium (51).
In our study, both peptides were associated with the process
of retinal differentiation, as indicated by the development of
axons and dendrites.
We also localized aFGF and bFGF to the epitheliumofthe
anterior of the lens, especially in the extracellular matrix.
aFGF has previously been extracted from adult bovine lens
(7) and the lens epithelium of the 6-wk-old rat expresses
aFGF but not bFGF mRNA (42) . Both FGFs are mitogenic
for lens epithelial cells in vitro (41) .
In the present study we localized aFGF and bFGF to all
the layers of the cornea. Gospodarowicz found bFGF to be
mitogenic forcorneal epitheliumand endothelium (26). Naji
et al. localized aFGF mRNA to the basal epithelial cells of
the anterior cornea ofthe 6-wk-old rat, but found no expres-
sion of bFGF in these cells (43). Caruelle et al . localized
aFGF immunoreactivity in the basal cells but not in Bow-
man's or Descemet's membranes (7), where Folkman et al.
had found bFGF immunoreactivity (20) . These adult distri-
butions clearly differ from those we observed in the em-
bryonic cornea.
7FssuesofMesodermalOrigin.Although exogenous aFGF
is mitogenic for mesenchymal cells in vitro and induces meso-
derm when added to Xenopus explant, aFGF could not be
detected in Xenopus oocytes and early embryos whereas
bFGF was detected (37, 55, 56) . Thus, the role of endoge-
nous aFGF in the development ofmesodermal tissues remains
unclear. In the present investigation, immunoreactive aFGF
was identified in all mesodermal tissues throughout embry-
onic development. At later stages of development, however,
immunoreactivity for aFGF became less intense in some lin-
zone or middle layer (M) and the white zone (W), and it is negative in the less differentiated ependyma (E) . (e) Section ofthe myocardium
of 20-d embryo stained with Ab ií63; staining is positive in the myocytes, in most endothelial cells of the endocardium and capillaries,
and in the extracellular matrix. (f) Section of the digestive system of 18-d embryo stained with Ab #63; staining is positive in the mesen-
chyrnal tissue and negative in the epithelium. Bars, 50 ttm.
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reactive bFGF in 11- and 15-d ratembryo (e andf) . (a) Cross section of 17-d embryo at neck level stained with Ab 1x63 ; staining is intense
in the connective tissue surrounding the trachea (T) and esophagus (E) ; It is faint in the chondrocytes of the trachea and in the smooth
muscle ofthe mediaof a large artery (A); it is negative in the epithelium of trachea and esophagus. (b) Hind limb of 18-d embryo stained
withAb #119 ; staining is intense in the ossification center (arrow)and is also positive inthe skeletal muscle (M) . (c)Lungsof 18-d embryo
stained with Ab #119 ; staining is positive in the mesenchymal tissue of the lungsand is negative in the epithelium of airways. (d) Thymus
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yet known whether this indicates a decline in the synthesis
and use of aFGF, it is noteworthy that bFGF delays skeletal
myoblast differentiation in vitro (9) and receptors for aFGF
and bFGF decline in number with differentiation of non-
neural tissues (44).
In other tissues of mesodermal origin, such as the bones,
the pattern of immunoreactivity for aFGF also showed pro-
gressive changes during development. Immunostaining was
less intense and homogenous in the differentiating and pro-
liferating chondroblasts than in the undifferentiated mesen-
chymal cells, and staining was absent in the perichondrium
and periosteum. At later stages, however, immunostaining
became again intensely positive in the ossification centers.
These findings suggest that aFGF, which has previously been
extracted from bone and cartilage (28, 49), may have differ-
ent roles in bone development, including stimulation ofchon-
droblast and osteoblast proliferation, as well as stimulation
of the angiogenesis that precedes ossification (3, 6, 24).
aFGF has previously been extracted from kidneys (21,
47) . In the present study, inununoreactivity for aFGF in the
kidneys, like in the bones, appeared to be inversely related
to cell differentiation . For example, cells that are highly
differentiated, such as the epithelial cells of the glomeruli ,
and tubules of the cortex, showed no immunoreactivity for
aFGR Conversely, less differentiated mesenchymal cells of
the medulla showed intense and uniform staining. These find-
ings are interesting in lightofprevious observations showing
that the mesenchyme triggers the differentiation of renal pri-
mordia into nephrons (50).
Immunoreactive aFGF was also notedin many endothelial
cells. The angiogenic effect of adding FGFs to the avascular
cornea is well known(5, 19, 26). However, many factors are
angiogenic and the role of endogenous bFGF has yet to be
clarified. aFGF has not been detected in most endothelial
cells (19, 26, 34), with one exception (3) . We did not examine
the early stages ofvasculogenesis, but during angiogenic in-
vasion ofdeveloping brain, spinal cord, and bone intense en-
dothelial aFGF immunostaining was noted. Some cells were
unstained, perhaps due to restriction of aFGF expression to
specific stages of the cell cycle; or the absence of this growth
factor coulddenote endothelial cellsdestined for programmed
cell death in the stage when some capillaries regress and
others develop into arterioles and venules.
The differences in the distribution ofimmunoreactive aFGF
that we identified in cells and tissues of mesodermal origin
have important implications, since they suggest that aFGFs
regulatory effects may be tissue specific.
Tissues ofEndodermal Origin. In higher organisms, the
epithelial cells that coverthe inner surfaces ofthe respiratory
and digestive systems and the distal portion of the urinary
system (bladder and urethra) originate from the endoderm.
The epithelial cells of the thymus and thyroid, and the func-
tional cellular elements of all the digestive glands (including
pancreas and liver) are also of endodermal origin. At all
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stages examined, the cellsof endodermal origin were devoid
of immunoreactive aFGR However, aFGF was expressed in
the mesoderm-derived tissues (such as the connectivetissue)
of these organs. Moreover, embryonic endodermal deriva-
tives may have FGF receptors, since aFGF is mitogenic for
hepatocytes in vitro (31, 44) . In addition, in vivo infusion
of neutralizing antisera to bFGF has been shown to disrupt
the development of endoderm-derived tissues (39). The ab-
senceofFGFs in endoderm-derivedtissues seems to contrast
with the mounting evidence that bFGF is one of the signals
by which the endoderm induces mesoderm formation in
Xenopus (36, 55) . Since there are substantial differences in
gastrulation between toad and rat, it is possible that neither
bFGF nor aFGF play a role in rat gastrulation, or that these
two peptides are not present in the endoderm, but stored in
the ectoderm and activated by a substance released by the
endoderm. Therefore, although we could not identify immu-
noreactive aFGF in tissues of endodermal origin, these pre-
vious observations suggest that aFGF may have a role in the
growth and differentiation of these tissues.
Comparison ofImmunohistochemicalLocalization
ofaFGFandbFGF
Previous observations indicate that, like aFGF, bFGF may
play important roles in differentiation and growth of em-
bryonic tissues of neuroectodermal and mesodermal origin
(55, 56) . In the present investigation, we have compared the
cellular and tissue distribution of bFGF with that of aFGF
in rat embryos at different stages. Each of the several anti-
bodies used in the present study identified a very similar cel-
lularand tissue distribution ofthese peptides during develop-
ment, and each peptide was widely distributed in tissues of
neuroectodermal and mesodermal origin. The similarities in
the distribution of immunoreactive aFGF and bFGF we
identified in the rat embryo are consistent with their similar
mitogenic and chemotactic effects on cells of mesodermal
and neuroectodermal origin in vitro (5, 26). In addition,
these similarities are consistent with the results of previous
studies of 18-d rat embryo (25).
Conclusions
The findings of the present study indicate that 26-28-kD im-
munoreactive aFGF and bFGF are probably themain natural
forms of these peptides in the rat embryo. In addition, our
comparative analysis of the cellular and tissue distribution
ofimmunoreactive aFGF and bFGF demonstrates that these
peptides have a widespread and similar distribution in neu-
roectodermal and mesodermaltissues ofthe rat embryo. Fi-
nally, our results show progressive and similarchanges in the
distribution of these peptides during embryonic develop-
ment, and such changes appear to be associated with the
processes of cell growth, migration, and differentiation.




of 19-d embryo stained with Ab #63 ; staining is negative in this organ. (e) Serial sagittal section of 11-d embryo stained with Ab #773
for bFGF; staining is positive in the heart and surrounding mesenchymal tissues, the distribution of staining is superimposable to that
of aFGF in Fig. 5 a. (f) Serial section stained with Ab #967 for bFGF; distribution of staining is similar to that of aFGF (Fig. 4 a).
Bars, 50 Am.Received for publication 24August 1990and inrevisedform24 May 1991 .
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